MarkJMulliganMDFIDSA

HIV/AIDS Medicine, Microbiology

Director, NYU Langone Vaccine Center; Director, Division of Infectious Diseases and Immunology; Thomas S. Murphy, Sr. Professor of Medicine; Professor of Microbiology; Department of Medicine, NYU Langone School of Medicine

Join to view full profile

Dr. Mulligan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mulligan's full profile

Already have an account?

Office
NYU Langone Medical Center - Infectious Diseases and Immunology
Alexandria Center for Life Sciences (West Tower) 430 E 29th St, Room 304
New York, NY 10016
Phone+1 212-263-9410

Fax+1 646-501-4645

Education & Training

University of Alabama Medical CenterFellowship, Infectious Disease, 1987 - 1990
University of Alabama Medical CenterResidency, Internal Medicine, 1984 - 1987
University of Texas Southwestern Medical SchoolClass of 1984

Certifications & Licensure

NY State Medical License 2018 - 2026
GA State Medical License 2006 - 2019
AL State Medical License 1985 - 2006
TX State Medical License 1985 - 1987
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

A Study to Test the Safety of Three Experimental HIV Vaccines
Completed
Phase 1
Safety of an HIV DNA Vaccine Given to HIV Uninfected Adults
Completed
Phase 1
Yellow Fever Virus Vaccine and Immune Globulin Study Start of enrollment: 2006 Jun 01
Completed
Phase 1
Human Immune Responses to Yellow Fever Vaccination Start of enrollment: 2008 May 01
Recruiting
Phase 4
Systems Biology of PNEUMOVAX®23 and PREVNAR 13® Start of enrollment: 2014 Apr 01
Completed
Not Applicable
Immune Memory After Papillomavirus Vaccination Start of enrollment: 2012 Jan 01
Completed
Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of Antibiotics Start of enrollment: 2015 Apr 01
Completed
Not Applicable
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) Start of enrollment: 2015 May 01
Completed
Phase 2
Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies Start of enrollment: 2015 Oct 28
Completed
Phase 1
2013/2017 H7N9 Prime-Boost Interval Start of enrollment: 2018 Aug 21
Completed
Phase 2
New York City Observational Study of Mpox Immunity Start of enrollment: 2022 Nov 11
Recruiting
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised...
Richard T Davey Jr, Gary L Collins, Nadine Rouphael, Guillaume Poliquin, Rosemary McConnell
The Lancet. Microbe. 2024-11-01
1 citations
Vaccine Equity: Lessons Learned Exploring Facilitators and Barriers to COVID-19 Vaccination in Urban Black Communities.
Lalitha Parameswaran, Anna Jaysing, Helen Ding, Marc Wilkenfeld, Ranekka Dean
Journal of Racial and Ethnic Health Disparities. 2024-08-01
1 citations
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated...
Christina A Rostad, Robert L Atmar, Emmanuel B Walter, Sharon Frey, Jeffery L Meier
Clinical Infectious Diseases. 2024-06-14

Press Mentions

5 Unusual Covid Symptoms — and What to Do About ThemNovember 16th, 2022
Meissa Appoints Drs. Dan H. Barouch and Mark J. Mulligan to Scientific Advisory BoardDecember 16th, 2021
This Is How Long After Your Vaccination You’ll Need a Booster Shot in the USAugust 19th, 2021
Join now to see all

Grant Support

Clinical And StatisticalNational Institute Of Allergy And Infectious Diseases2011
Training A New Generation Of VaccinologistsNational Institute Of Allergy And Infectious Diseases2009–2011
Clinical And StatisticalNational Institute Of Allergy And Infectious Diseases2009–2011
Vaccine And Treatment Evaluation UnitsNational Institute Of Allergy And Infectious Diseases2009
Clinical Research CoreNational Institute Of Allergy And Infectious Diseases2008
Alabama/Zambia HIV Vaccine Clinical Trials Unit (HVTU)National Institute Of Allergy And Infectious Diseases2000–2003
AIDS Vaccine Evaluation UnitsNational Institute Of Allergy And Infectious Diseases1994–2000
Glycoproteins In HIV-2 Assembly, Binding, And FusionNational Institute Of Allergy And Infectious Diseases1994–1996
HIV-2 Envelope Glycoproteins And Cell FusionNational Institute Of Allergy And Infectious Diseases1988–1992